24 results
10-Q
2024 Q1
EX-10.3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
not create any conflict of interest with Executive’s duties to the Company; provided, however, that Executive may invest in index funds without regard
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise … to a conflict of interest. Such policy provides that any request for us to enter into a transaction with an executive officer, director, nominee
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise … to a conflict of interest. Such policy provides that any request for us to enter into a transaction with an executive officer, director, nominee
10-K
2023 FY
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Annual report
4:48pm
. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected … it is inappropriate for our audit committee to review such transaction due to a conflict of interest. Such policy provides that any request for us
8-K
EX-3.2
CHRO
Chromocell Therapeutics Corp.
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
be in compliance, if elected as a director of the Corporation, and will comply with, all applicable publicly disclosed corporate governance, conflict … of interest, confidentiality and stock ownership and trading policies and guidelines of the Corporation.
(e) A person shall not be eligible
424B4
6wiwgl6ip07qma6n
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
huqzcr mhby2pxm
20 Feb 24
Prospectus supplement with pricing info
5:28pm